Amgen Inc is primarily active in the biotechnology industry.

The main competitors of Amgen Inc in the market are Johnson & Johnson, Novartis AG, Pfizer Inc, and Roche Holding AG.

Amgen Inc. is a biotechnology company that was founded in 1980. It has its headquarters in Thousand Oaks, California. The company specializes in developing and manufacturing human therapeutics. Amgen Inc. has a rich history of groundbreaking innovations and advancements in the field of biotechnology. It has introduced numerous successful drugs and therapies, including Epogen, Neupogen, and Enbrel, which have had a significant impact on the treatment of various diseases. Amgen Inc. has grown into one of the largest biotechnology companies globally and continues to strive for advancements in medical science to improve patients' lives.

Amgen Inc has achieved several significant milestones throughout its history. It pioneered the development and commercialization of biotechnology-based medicines, leading to groundbreaking treatments for various diseases. Notably, Amgen's introduction of Epogen revolutionized the treatment of anemia in patients with chronic kidney disease. The company also played a crucial role in advancing the science of targeted therapies with the launch of drugs like Neulasta and Neupogen, enhancing cancer patient care. Additionally, Amgen has expanded its portfolio with innovative drugs addressing osteoporosis, psoriasis, and migraine prevention. Through continuous research and advancements, Amgen Inc remains at the forefront of biopharmaceutical innovation.

Amgen Inc is primarily present in the United States, with its headquarters located in Thousand Oaks, California. The company also has a significant presence in various other countries and regions including Europe, Canada, Japan, and Australia. With a global reach, Amgen Inc operates in many key markets worldwide, leveraging its expertise and innovative portfolio of biopharmaceutical products to improve patients' lives.

Amgen Inc represents values such as integrity, excellence, and a commitment to patients. The corporate philosophy of Amgen focuses on innovative science, delivering life-changing medicines, and addressing unmet medical needs. Amgen aims to improve the health and well-being of individuals worldwide through their cutting-edge research and development efforts. With a strong emphasis on scientific rigor, ethical practices, and patient-centered approach, Amgen is dedicated to pioneering breakthrough therapies to advance medical care and make a positive impact on society.

Analysts currently set an average price target of 360.25 USD for the Amgen stock (median: 360.06 USD), implying -6.5 % versus the latest price. The consensus is based on 41 analyst ratings.

Amgen Analyst Price Targets 2026

42 analysts currently rate the Amgen stock: 21 recommend buying, 18 holding and 3 selling. For 2026, analysts expect Amgen to generate revenue of 37.76 B USD and earnings per share of 22.30 USD.

Amgen Analyst Price Targets 2026

Converted at the current exchange rate, the Amgen share trades at 329.86 EUR (380.62 USD).

The Amgen share (AMGN) is listed on 10 stock exchanges, including: NASDAQ (AMGN), XETRA (AMG.DE), Frankfurt (AMG.F), München (AMG.MU), Düsseldorf (AMG.DU), Hamburg (AMG.HM), London (0R0T.L), SIX (Zürich) (AMGN.SW).

Amgen Inc. is a biotechnology company that focuses on the development, manufacturing, and marketing of biopharmaceuticals. The company was founded in 1980 and is headquartered in Thousand Oaks, California. Amgen is a key player in the biotechnology field with over 21,000 employees worldwide. Amgen has several divisions, including oncology, hematology, nephrology, bone metabolism, and inflammation. In oncology, Amgen offers various drugs for the treatment of cancer, including Blincyto, Vectibix, and Neulasta. In hematology, the company has developed Aranesp and Epogen for the treatment of anemia. Additionally, Amgen also offers various products for the treatment of kidney diseases such as Sensipar and Parsabiv. In the field of bone metabolism, Amgen provides medications for the treatment of osteoporosis, such as Prolia and Xgeva. In the field of inflammation, Amgen has developed Enbrel for the treatment of rheumatoid arthritis and other inflammatory diseases. Amgen also holds a significant position in the biosimilars market. Biosimilars are imitations of biological drugs that are already on the market. They allow patients to access more affordable treatment options while still providing the same effectiveness and safety as the original product. Amgen has several biosimilars on the market, including Amgevita and Mvasi. Amgen's business model is based on the development of new biopharmaceuticals and biosimilars. The company invests significant financial resources in research and development to create innovative products that aim to improve the health and well-being of patients. Amgen also collaborates closely with other companies and research institutions to find creative solutions for medical challenges. To implement its business model, Amgen has built a global network of production and distribution centers to distribute its products worldwide. The company also has a team of disease-fighting experts, as well as researchers and engineers who work closely together to develop and improve new products. Overall, Amgen has a strong business model based on the development of biopharmaceuticals and biosimilars. The company produces high-quality products to enhance the health of patients worldwide. With a dedicated team of professionals focusing on research, development, and disease-fighting, Amgen is well-positioned to continue creating innovative solutions for medical challenges and expanding its market share.

The expected revenue of Amgen is 37.76 B USD. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Amgen is 12.11 B USD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Amgen is currently 17.07. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Amgen stock.

The price-to-sales ratio (P/S) of Amgen is currently 5.47. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Amgen stock.

The Eulerpool Quality Score for Amgen is 6/10.

The ISIN of Amgen is US0311621009. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of Amgen is 867900. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of Amgen is AMGN. The ticker symbol is used to trade Amgen shares on the stock exchange.

Over the past 12 months, Amgen paid a dividend of 9.52 USD . This corresponds to a dividend yield of about 2.50 %. For the coming 12 months, Amgen is expected to pay a dividend of 10.89 USD.

The current dividend yield of Amgen is 2.50 %.

Amgen pays a dividend, distributed in the months of , , , .

Amgen paid dividends every year for the past 15 years.

For the upcoming 12 months, dividends amounting to 10.89 USD are expected. This corresponds to a dividend yield of 2.83 %.

Amgen is assigned to the 'Health' sector.

To receive the latest dividend of Amgen from amounting to 2.52 USD, you needed to have the stock in your portfolio before the ex-date on .

The last dividend was paid out on .

In the year 2025, Amgen distributed 9.13 USD as dividends.

The dividends of Amgen are distributed in USD.